Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A mixture of low-molecular-weight neuropeptides and amino acids derived from purified pig brain proteins. Approved as a drug in over 50 countries (including much of Europe and Asia) for stroke, traumatic brain injury, and Alzheimer's disease. One of the most clinically studied neuropeptide preparations in the world.
A synthetic heptapeptide analog of tuftsin developed by the Institute of Molecular Genetics in Russia. Approved in Russia as an anxiolytic and nootropic. Widely used for anxiety reduction and cognitive enhancement without sedation.
Acts as a neurotrophic factor, mimicking the effects of BDNF, NGF, and other endogenous growth factors. Promotes neuronal survival, synaptic plasticity, and neurogenesis. Reduces excitotoxicity and oxidative stress in neural tissue. Crosses the blood-brain barrier due to its small molecular weight.
Modulates GABA-A receptor activity and increases BDNF expression. Stabilizes enkephalins (endogenous opioid peptides) by inhibiting their enzymatic breakdown, prolonging their anxiolytic effects. Also modulates serotonin, dopamine, and norepinephrine systems.
- Stroke recovery and rehabilitation
- Traumatic brain injury recovery
- Alzheimer's disease (approved in some countries)
- Cognitive enhancement
- Neuroprotection
- Anxiety and stress reduction
- Cognitive enhancement and focus
- Depression support
- Immune system modulation
- Memory improvement
- Derived from porcine brain — religious/ethical considerations for some
- Injection site reactions
- Rare allergic reactions
- Seizure risk at high doses (rare)
- Not FDA-approved — quality of gray-market sources varies significantly
- Limited Western clinical trial data
- Nasal spray may cause mild irritation
- Potential fatigue at higher doses
- Long-term safety profile not established in Western populations
- Interactions with other anxiolytics not well characterized
Not FDA-approved in the United States. Approved as a prescription drug in 50+ countries including Germany, Austria, Russia, China, and most of Eastern Europe and Asia. Available in the US only as a research chemical or through international sources. Has the most robust clinical evidence base of any compound in the nootropic peptide category.
Not FDA-approved and not currently on any FDA compounding list. Available as a research chemical. Approved in Russia as an anxiolytic drug. Not affected by the April 2026 Category 2 removal action.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.